Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2022-07-01 AGM Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ w dniu 28.06.2022 r. - Content (PL)
AGM Information Classification · 99% confidence The document text is very short (383 characters) and explicitly states that the Management Board of PHARMENA S.A. is attaching a list of shareholders holding at least 5% of the votes from the Annual General Meeting (Zwyczajnym Walnym Zgromadzeniu) held on 28.06.2022. This content—announcing the results of voting rights or shareholder structure following a meeting—fits best under Declaration of Voting Results & Voting Rights Announcements (DVA). It is not the full AGM presentation (AGM-R) or a general regulatory filing (RNS), but a specific outcome announcement.
2022-07-01 Polish
220628_PHR_Informacje o Członkach RN
Board/Management Information Classification · 98% confidence The document text is in Polish and details the appointment information, qualifications, professional history, and external activities for several individuals (Jacek Dauenhauer, Agnieszka Dziki, Jerzy Gębicki, Anna Janicka) who are identified as 'Członek Rady Nadzorczej' (Member of the Supervisory Board) of the issuing company (Pharmena S.A. is mentioned). This structure—providing detailed biographical and conflict-of-interest information for board members—is characteristic of disclosures related to corporate governance and board composition changes. This aligns directly with the 'Board/Management Information' category (MANG), which covers announcements of changes in the company's board of directors or senior management. The reference to Polish regulations ('Rozporządzenia Ministra Finansów') confirms it is a formal regulatory disclosure concerning management structure.
2022-06-29 Polish
Powołanie członków Rady Nadzorczej na nową kadencję - Content (PL)
Board/Management Information Classification · 98% confidence The document text explicitly states that the Management Board of PHARMENA S.A. is informing about the Annual General Meeting (Zwyczajne Walne Zgromadzenie) held on June 28, 2022. The core content is the resolution (uchwałę nr 16) regarding the appointment of the new Supervisory Board (Rada Nadzorcza) members for a new term. This directly relates to changes in the company's board of directors or senior management. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short (1115 chars), but it contains the substantive information about the appointments, not just an announcement that the information is attached, making MANG more specific than RPA or RNS.
2022-06-29 Polish
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 28 06 2022
AGM Information Classification · 99% confidence The document text is titled "Uchwały podjęte przez Zwyczajne Walne Zgromadzenie" (Resolutions adopted by the Annual General Meeting) and details several resolutions passed on June 28, 2022, concerning the approval of annual reports, financial statements for the period ending 31.12.2021, and the granting of discharge (absolutorium) to a board member. The key phrases are "Zwyczajne Walne Zgromadzenie" (Annual General Meeting) and the detailed voting results on resolutions. This content directly relates to the proceedings and outcomes of an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is substantial (41,698 chars), indicating it is the actual record/minutes, not just a brief announcement (RPA/RNS).
2022-06-29 Polish
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 28.06.2022 r. - Content (PL)
AGM Information Classification · 99% confidence The document text explicitly states that the Management Board of PHARMENA S.A. is providing the content of the resolutions ('treść uchwał') adopted by the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie') held on June 28, 2022. This directly relates to the outcomes of a shareholder meeting. The most specific category for official results from a general meeting is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it contains the resolutions, the context is the announcement of the results/decisions made at the AGM.
2022-06-29 Polish
220623_PHR_Kandydaci_RN_informacje
Board/Management Information Classification · 98% confidence The document text is titled "Informacje o kandydatach na Członków Rady Nadzorczej spółki PHARMENA S.A. z siedzibą w Łodzi" (Information about candidates for Members of the Supervisory Board of PHARMENA S.A. based in Łódź). It details the qualifications, previous roles, and declarations of three candidates (Jacek Dauenhauer, Agnieszka Dziki, and Jerzy Gębicki) for positions on the Supervisory Board. This content directly relates to the composition and governance structure of the company's oversight body, which falls under the scope of Board/Management Information (MANG) or Governance Information (CGR). Since it specifically concerns the nomination and background of Supervisory Board members, it is most accurately classified as Board/Management Information (MANG), as it announces changes or candidates for management/supervisory roles. It is not a general governance report (CGR) or a proxy statement (PSI), but rather specific biographical and suitability information for new/re-appointed board members.
2022-06-23 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.